{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:04:54Z","timestamp":1791198294786,"version":"4.1.0"},"reference-count":42,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":4042,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes. In the present study, we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>EndoMT was induced in a mouse pancreatic microvascular endothelial cell line (MMEC) in the presence of advanced glycation end products (AGEs) and in the endothelial lineage\u2013traceble mouse line Tie2-Cre;Loxp-EGFP by administration of AGEs, with nonglycated mouse albumin serving as a control. Phosphorylated Smad3 was detected by immunoprecipitation\/Western blotting and confocal microscopy. Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Confocal microscopy and real-time PCR demonstrated that AGEs induced EndoMT in MMECs and in Tie2-Cre;Loxp-EGFP mice. Immunoprecipitation\/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of nephropathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>EndoMT is a novel pathway leading to early development of diabetic nephropathy. Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db09-1631","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T02:16:38Z","timestamp":1280888198000},"page":"2612-2624","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":230,"title":["Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy"],"prefix":"10.2337","volume":"59","author":[{"given":"Jinhua","family":"Li","sequence":"first","affiliation":[{"name":"Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Caruana","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon D.","family":"Ricardo","sequence":"additional","affiliation":[{"name":"Monash Immunology and Stem Cell Laboratories, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Bertram","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"2022031211385484400_B1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2353\/ajpath.2009.090698","article-title":"Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy","volume":"175","author":"Kizu","year":"2009","journal-title":"Am J Pathol"},{"key":"2022031211385484400_B2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031211385484400_B3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031211385484400_B4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031211385484400_B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031211385484400_B6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0272-6386(97)90466-2","article-title":"Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy","volume":"29","author":"Pedagogos","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2022031211385484400_B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ndt\/12.1.43","article-title":"Myofibroblasts and the progression of diabetic nephropathy","volume":"12","author":"Essawy","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2022031211385484400_B8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm1613","article-title":"Endothelial-to-mesenchymal transition contributes to cardiac fibrosis","volume":"13","author":"Zeisberg","year":"2007","journal-title":"Nat Med"},{"key":"2022031211385484400_B9","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1681\/ASN.2008050513","article-title":"Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition","volume":"19","author":"Zeisberg","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2022031211385484400_B10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2353\/ajpath.2009.090096","article-title":"Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice","volume":"175","author":"Li","year":"2009","journal-title":"Am J Pathol"},{"key":"2022031211385484400_B11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1043-2760(00)00311-8","article-title":"RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes","volume":"11","author":"Schmidt","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"2022031211385484400_B12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0272-6386(95)90051-9","article-title":"Advanced glycosylation end products in diabetic renal and vascular disease","volume":"26","author":"Bucala","year":"1995","journal-title":"Am J Kid Dis"},{"key":"2022031211385484400_B13","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2337\/db06-0221","article-title":"RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low\u2013molecular weight heparin","volume":"55","author":"Myint","year":"2006","journal-title":"Diabetes"},{"key":"2022031211385484400_B14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI11951","article-title":"Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)","volume":"108","author":"Oldfield","year":"2001","journal-title":"J Clin Invest"},{"key":"2022031211385484400_B15","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.96.7.2262","article-title":"Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE","volume":"96","author":"Bierhaus","year":"1997","journal-title":"Circulation"},{"key":"2022031211385484400_B16","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1016\/S0021-9258(17)36966-1","article-title":"Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors\/binding proteins","volume":"269","author":"Yan","year":"1994","journal-title":"J Biol Chem"},{"key":"2022031211385484400_B17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2337\/diabetes.52.3.621","article-title":"Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42\/44 MAPK, and nuclear factor-\u03baB in PBMCs","volume":"52","author":"Schiekofer","year":"2003","journal-title":"Diabetes"},{"key":"2022031211385484400_B18","doi-asserted-by":"crossref","first-page":"19919","DOI":"10.1074\/jbc.274.28.19919","article-title":"Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-\u03baB require the cytoplasmic domain of the receptor but different downstream signaling pathways","volume":"274","author":"Huttunen","year":"1999","journal-title":"J Biol Chem"},{"key":"2022031211385484400_B19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"2022031211385484400_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0047-6374(01)00366-9","article-title":"Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes","volume":"1","author":"Stern","year":"2002","journal-title":"Ageing Res Rev"},{"key":"2022031211385484400_B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.0000137876.28454.64","article-title":"Protein glycation. A firm link to endothelial cell dysfunction","volume":"95","author":"Wautier","year":"2004","journal-title":"Circ Res"},{"key":"2022031211385484400_B22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2796.2003.01301.x","article-title":"Amphoterin as an extracellular regulator of cell motility: from discovery to disease","volume":"255","author":"Huttunen","year":"2004","journal-title":"J Intern Med"},{"key":"2022031211385484400_B23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1681\/ASN.2006050459","article-title":"Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy","volume":"18","author":"Nakagawa","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022031211385484400_B24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1096\/fj.02-1117fje","article-title":"Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease","volume":"18","author":"Li","year":"2004","journal-title":"FASEB J"},{"key":"2022031211385484400_B25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0006-291X(03)00885-4","article-title":"Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy","volume":"305","author":"Fujimoto","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2022031211385484400_B26","doi-asserted-by":"crossref","first-page":"F1657","DOI":"10.1152\/ajprenal.00274.2007","article-title":"Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria","volume":"293","author":"Wang","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031211385484400_B27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1172\/JCI200319270","article-title":"Targeted disruption of TGF-beta1\/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction","volume":"112","author":"Sato","year":"2003","journal-title":"J Clin Invest"},{"key":"2022031211385484400_B28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/mol.105.017483","article-title":"Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression","volume":"69","author":"Jinnin","year":"2006","journal-title":"Mol Pharmacol"},{"key":"2022031211385484400_B29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2353\/ajpath.2007.060481","volume":"170","author":"Kanetsuna","year":"2007","journal-title":"Am J Pathol"},{"key":"2022031211385484400_B30","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031211385484400_B31","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1001\/archinte.1993.00410210044006","article-title":"Angiotensin-converting enzyme inhibition and renal protection: an assessment of implications for therapy","volume":"153","author":"Hollenberg","year":"1993","journal-title":"Arch Intern Med"},{"key":"2022031211385484400_B32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1159\/000117461","article-title":"Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis","volume":"28","author":"Jerums","year":"2008","journal-title":"Am J Nephrol"},{"key":"2022031211385484400_B33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/labinvest.3700549","article-title":"Renal p38 MAP kinase activity in experimental diabetes","volume":"87","author":"Komers","year":"2007","journal-title":"Lab Invest"},{"key":"2022031211385484400_B34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00125-004-1437-0","article-title":"Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy","volume":"47","author":"Adhikary","year":"2004","journal-title":"Diabetologia"},{"key":"2022031211385484400_B35","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1053\/ajkd.2001.27438","article-title":"Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway","volume":"38","author":"Haneda","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2022031211385484400_B36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/sj.ki.5000329","article-title":"Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries","volume":"69","author":"Lin","year":"2006","journal-title":"Kidney Int"},{"key":"2022031211385484400_B37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1681\/ASN.2008040445","article-title":"PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells","volume":"20","author":"Wu","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022031211385484400_B38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00125-009-1278-y","article-title":"Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice","volume":"52","author":"Meier","year":"2009","journal-title":"Diabetologia"},{"key":"2022031211385484400_B39","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1046\/j.1523-1755.2003.00016.x","article-title":"Role of TGF-beta signaling in extracellular matrix production under high glucose conditions","volume":"63","author":"Li","year":"2003","journal-title":"Kidney Int"},{"key":"2022031211385484400_B40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.devcel.2009.05.010","article-title":"Essential role of TGF-beta signaling in glucose-induced cell hypertrophy","volume":"17","author":"Wu","year":"2009","journal-title":"Dev Cell"},{"key":"2022031211385484400_B41","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db08-0057","article-title":"Oxidative stress as a major culprit in kidney disease in diabetes","volume":"57","author":"Forbes","year":"2008","journal-title":"Diabetes"},{"key":"2022031211385484400_B42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(98)01346-4","article-title":"Pathogenesis, prevention, and treatment of diabetic nephropathy","volume":"352","author":"Cooper","year":"1998","journal-title":"Lancet"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/59\/10\/2612\/396816\/zdb01010002612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/59\/10\/2612\/396816\/zdb01010002612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:21:33Z","timestamp":1667406093000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/59\/10\/2612\/16971\/Blockade-of-Endothelial-Mesenchymal-Transition-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,3]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,8,3]]},"published-print":{"date-parts":[[2010,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db09-1631","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,3]]}}}